Engineering a "muco‐trapping" ACE2‐immunoglobulin hybrid with picomolar affinity as an inhaled, pan‐variant immunotherapy for COVID‐19

• Main Authors: Karthik Tiruthani (Author), Carlos Cruz‐Teran (Author), Jasper F. W. Chan (Author), Alice Ma (Author), Morgan McSweeney (Author), Whitney Wolf (Author), Shoufeng Yuan (Author), Vincent K. M. Poon (Author), Chris C. S. Chan (Author), Lakshmi Botta (Author), Brian Farrer (Author), Ian Stewart (Author), Alison Schaefer (Author), Jasmine Edelstein (Author), Priya Kumar (Author), Harendra Arora (Author), Jeff T. Hutchins (Author), Anthony J. Hickey (Author), Kwok‐Yung Yuen (Author), Samuel K. Lai (Author)
• Format: Book
• Published: Wiley, 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Soluble angiotensin‐converting enzyme 2 (ACE2) can act as a decoy molecule that neutralizes severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) by blocking spike (S) proteins on virions from binding ACE2 on host cells. Based on structural insights of ACE2 and S proteins, we designe...